VANCOUVER, BC / ACCESS Newswire / April 27, 2026 / Core Silver Corp. (CSE:CC)(FSE:8ZR)(OTCQB:CCOOF) ("Core Silver") and Arcus Development Group Inc. (TSXV:ADG) ("Arcus", and together with Core Silver, ...
Arcus’s pipeline includes several promising candidates, including domvanalimab, an Fc-silent anti-TIGIT antibody, and zimberelimab, an anti-PD-1 antibody. Arcus recently announced positive results ...
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis of ...
In April 2026, Arcus Biosciences said Gilead Sciences chose not to make a continuation payment, ending option rights to ...
Zacks Investment Research on MSN
Arcus Biosciences (RCUS) moves 7.8% higher: Will this strength last?
Arcus Biosciences, Inc. (RCUS) shares ended the last trading session 7.8% higher at $24.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
(RTTNews) - Gilead Sciences, Inc. (GILD) and Arcus Biosciences (RCUS) Monday announced a positive update for the randomized, open-label joint TIGIT Phase 2 ARC-7 study in patients with first-line ...
HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS) today announced that data from cohort A1 of the ongoing Phase 2 EDGE-Gastric study will be presented at the American Society of ...
Gilead Sciences and Arcus are slimming down a phase 3 TIGIT trial to compare the lung cancer combo therapy to just Merck’s Keytruda, ditching a chemotherapy arm. The move means a little extra cash ...
Arcus Biosciences, Inc. (RCUS) shares ended the last trading session 7.5% higher at $18.6. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results